• 亿邦公众号
    • APP下载

中国市场营收连年收窄 屈臣氏母公司公布2024年财报

作者:张从容 文章来源:亿邦动力

2025-03-23 22:05

作者:张从容 文章来源:亿邦动力

2025-03-23 22:05

邦小白快读

EN
全文速览

财报关键数据显示屈臣氏全球业务增长但中国市场表现疲软。

1. 2024年屈臣氏母公司零售部门收益总额1901.93亿港元,同比增长4%;EBITDA163.95亿港元,同比增长1%。

2. 全球店铺数目16951家,对比2023年新增460家;计划今年新增500家门店,远超往年水平。

3. 中国市场美容及保健产品收益135.08亿港元,同比收窄17.9%,自2021年起连年下降;EBITDA4.67亿港元,同比收窄55.18%。

4. 中国及亚洲市场收益总额508.7亿港元,同比收窄1.58%;亚洲其他地区收益373.62亿港元,同比增长6.04%。

5. 欧洲市场收益1771.87亿港元,同比增长7.98%,显示区域分化明显。

市场分化揭示消费趋势变化和海外拓展机会。

1. 中国市场美容保健产品收入连续收窄,反映消费需求减弱或竞争加剧,品牌需调整营销策略。

2. 亚洲其他地区收益增长6.04%,欧洲增长7.98%,提示品牌可关注这些高增长市场的渠道建设和产品研发机会。

3. 门店扩张计划(今年新增500家)涉及品牌渠道优化,可能带来定价和合作新空间。

4. 用户行为观察:收入数据暗示消费者偏好可能转向其他渠道,品牌应监测趋势变化。

财报提供风险提示和增长市场机会,卖家可调整策略应对。

1. 风险提示:中国市场收益大幅收窄17.9%,EBITDA下降55.18%,需谨慎评估市场进入风险。

2. 机会提示:欧洲市场收益增长7.98%,亚洲其他地区增长6.04%,是潜在增长点,可拓展销售渠道。

3. 事件应对措施:计划新增500家门店,远超往年水平,卖家可探索合作或招商机会。

4. 正面影响:全球收益整体增长4%,显示实体零售商业模式仍有韧性,可学习其扩张策略。

市场变化影响产品需求,工厂可关注海外生产机会。

1. 中国市场收入连续收窄,可能减少对美容保健产品的生产需求,工厂需优化设计以应对需求下滑。

2. 商业机会:欧洲和亚洲其他地区收益增长,提示出口或本地化生产机会,工厂可拓展这些区域供应链。

3. 推进数字化启示:门店扩张计划涉及电商整合,工厂可考虑供应链数字化以支持高效运营。

4. 收入数据揭示区域分化,工厂应调整生产布局以适应市场动态。

行业趋势显示市场分化,服务商可解决客户痛点。

1. 行业发展趋势:中国市场收益收窄而欧洲增长7.98%,亚洲其他地区增长6.04%,显示区域不平衡动态。

2. 客户痛点:中国市场收入连续下降,痛点如需求下滑或竞争激烈,服务商需提供针对性分析服务。

3. 解决方案:基于趋势,服务商可开发市场监测工具,帮助客户规避风险并抓住增长机会。

4. 数据案例:EBITDA变化(中国下降55.18%)可作为痛点案例,指导服务优化。

市场动态启示运营管理和风险规避策略。

1. 商业需求:中国市场收益收窄17.9%,可能影响平台招商,平台需调整区域策略以吸引商家。

2. 风险规避:中国市场疲软(EBITDA下降55.18%)提示平台应规避高风险区域,转向欧洲等增长市场。

3. 平台招商机会:门店扩张计划(新增500家)涉及合作需求,平台可探索招商或运营支持。

4. 运营管理:全球收益增长4%显示实体零售潜力,平台可学习管理经验以优化服务。

财报揭示产业新动向和商业模式问题,引发研究启示。

1. 产业新动向:中国市场美容保健收入连续收窄,欧洲稳健增长7.98%,显示区域经济分化新问题。

2. 新问题:收入下降原因(如政策或消费习惯变化)需深入研究,可能涉及政策法规建议。

3. 商业模式:门店扩张计划(今年新增500家)显示对实体零售的持续投资,可分析其可持续性。

4. 政策启示:数据案例(如中国EBITDA下降55.18%)可建议政策调整以刺激市场活力。

声明:快读内容全程由AI生成,请注意甄别信息。如您发现问题,请发送邮件至 run@ebrun.com 。

我是 品牌商 卖家 工厂 服务商 平台商 研究者 帮我再读一遍。

Quick Summary

Watsons' global business shows growth while China market performance remains sluggish according to key financial data.

1. In 2024, Watsons' parent company recorded total retail revenue of HK$190.19 billion, up 4% year-on-year; EBITDA reached HK$16.40 billion, increasing 1%.

2. Global store count reached 16,951, adding 460 stores compared to 2023; the company plans to open 500 new stores this year, significantly exceeding previous years' levels.

3. China market beauty and health product revenue was HK$13.51 billion, down 17.9% year-on-year, marking consecutive declines since 2021; China EBITDA was HK$467 million, decreasing 55.18%.

4. China and Asia market total revenue was HK$50.87 billion, down 1.58%; other Asian regions generated HK$37.36 billion, growing 6.04%.

5. European market revenue reached HK$177.19 billion, up 7.98%, indicating clear regional divergence.

Market divergence reveals shifting consumer trends and overseas expansion opportunities.

1. China's beauty and health product revenue contraction reflects weakening demand or intensified competition, requiring brand marketing strategy adjustments.

2. Other Asian regions grew 6.04% and Europe grew 7.98%, suggesting brands should focus on channel development and product R&D in these high-growth markets.

3. Store expansion plans (500 new stores this year) involve channel optimization, potentially creating new pricing and partnership opportunities.

4. User behavior observation: Revenue data suggests possible consumer preference shifts to alternative channels, requiring ongoing trend monitoring.

Financial report provides risk warnings and growth market opportunities for strategic adjustments.

1. Risk alert: China market revenue declined 17.9% with EBITDA down 55.18%, requiring careful market entry risk assessment.

2. Opportunity indication: Europe grew 7.98% and other Asian regions grew 6.04%, representing potential growth points for sales channel expansion.

3. Strategic response: Planned 500 new store openings significantly exceed historical levels, creating partnership or distributor opportunities.

4. Positive impact: Global 4% revenue growth demonstrates physical retail resilience, offering expansion strategy insights.

Market changes impact product demand, highlighting overseas production opportunities.

1. China's continuous revenue contraction may reduce beauty/health product demand, requiring production optimization for declining needs.

2. Commercial opportunity: European and other Asian growth suggests export or localization potential for supply chain expansion.

3. Digital transformation: Store expansion involves e-commerce integration, suggesting supply chain digitization for operational efficiency.

4. Regional divergence in revenue data indicates need for production layout adjustments to adapt to market dynamics.

Industry trends show market divergence, creating client pain point solutions.

1. Industry development: China's contraction versus Europe's 7.98% and Asia's 6.04% growth reveals regional imbalance dynamics.

2. Client pain points: China's consecutive revenue declines indicate challenges like demand slump or competition, requiring targeted analytical services.

3. Solution development: Market monitoring tools can help clients mitigate risks and capture growth opportunities based on trends.

4. Data case study: China's 55.18% EBITDA decline serves as典型案例 for service optimization guidance.

Market dynamics inform operational management and risk avoidance strategies.

1. Business needs: China's 17.9% revenue contraction may affect merchant acquisition, requiring regional strategy adjustments.

2. Risk avoidance: China's weak performance (EBITDA down 55.18%) suggests shifting focus to growth markets like Europe.

3. Merchant acquisition opportunity: 500-store expansion plan creates partnership needs for platform collaboration or operational support.

4. Operational management: Global 4% revenue growth demonstrates physical retail potential for service optimization insights.

Financial report reveals industry developments and business model questions for research implications.

1. Industry动向: China's beauty/health revenue contraction versus Europe's 7.98% growth indicates new regional economic divergence issues.

2. Research questions: Causes of revenue decline (policy/consumption habit changes) require deeper study, potentially involving regulatory recommendations.

3. Business model analysis: 500-store expansion plan shows continued physical retail investment, warranting sustainability examination.

4. Policy implications: Data cases like China's 55.18% EBITDA decline may inform policy adjustments for market stimulation.

Disclaimer: The "Quick Summary" content is entirely generated by AI. Please exercise discretion when interpreting the information. For issues or corrections, please email run@ebrun.com .

I am a Brand Seller Factory Service Provider Marketplace Seller Researcher Read it again.

【亿邦原创】3月20日,屈臣氏母公司长江和记实业公布2024年全年财报。财报显示,2024年,母公司零售部门收益总额为1901.93亿港元,同比增长4%,EBITDA163.95亿港元,同比增长1%。

值得注意的是,2024年,屈臣氏集团在全球店铺数目为16951家,对比2023年新增460家。然而,据媒体报道,屈臣氏计划于今年新增500家门店。这一数字远超2022年至2024年间平均每年的新增门店数。

然而,屈臣氏的零售主营业务——美容及保健产品,在中国市场的营收情况并不乐观。财报显示,2024年,屈臣氏集团在中国美容保健产品收益总额为135.08亿港元,同比收窄17.9%,且自2021年起便连年收窄;EBITDA4.67亿港元,同比收窄55.18%。

中国市场的营收收窄,也拖累了中国及亚洲市场的收益情况:财报显示,2024年屈臣氏集团中国及亚洲美容及保健产品收益总额为508.7亿港元,同比收窄1.58%,然而亚洲市场收益总额为373.62亿港元,同比增长6.04%。

然而,屈臣氏在欧洲地区却增长稳健。2024年,屈臣氏欧洲美容及保健产品收益总额1771.87亿港元,同比增长7.98%。

亿邦持续追踪报道该情报,如想了解更多与本文相关信息,请扫码关注作者微信。

【版权提示】亿邦动力倡导尊重与保护知识产权。未经许可,任何人不得复制、转载、或以其他方式使用本网站的内容。如发现本站文章存在版权问题,烦请提供版权疑问、身份证明、版权证明、联系方式等发邮件至run@ebrun.com,我们将及时沟通与处理。

已点赞

+1

{{ praise_text }}

好文章,值得被更多人看到

FAQ回顾

屈臣氏2024年中国市场营收情况如何?

2024年屈臣氏中国美容保健产品收益总额为135.08亿港元,同比收窄17.9%,且自2021年起已连续多年收窄;EBITDA为4.67亿港元,同比大幅收窄55.18%。

屈臣氏2024年全球门店扩张计划是什么?

2024年屈臣氏全球店铺总数达16951家,新增460家;据媒体报道,公司计划2024年新增500家门店,远超2022-2024年平均年增数量。

屈臣氏欧洲市场2024年表现如何?

欧洲市场表现稳健,2024年美容保健产品收益总额达1771.87亿港元,同比增长7.98%,与亚太市场的收窄趋势形成对比。

广告

下一篇

征集报名《品牌数字化服务商资源手册》

《品牌数字化服务商资源手册》展示数字化服务商风采,亿邦全年零售大会通发,触达更多资源,马上加入!

马上入驻

追觅科技AWE2025展会上演“科技秀” 仿生机械手等创新成果引央视持续关注

在2025年中国家电及消费电子博览会(AWE2025)上,追觅科技凭借硬核创新实力强势 “出圈”,连续三日亮相央视,成为行业焦点。